Loxo Oncology Inc. (NASDAQ:LOXO) was up 2.8% during trading on Wednesday . The company traded as high as $26.89 and last traded at $26.51, with a volume of 53,954 shares. The stock had previously closed at $25.79.

A number of equities research analysts recently commented on LOXO shares. Cowen and Company reaffirmed a “buy” rating on shares of Loxo Oncology in a research note on Wednesday, July 13th. Zacks Investment Research raised Loxo Oncology from a “hold” rating to a “buy” rating and set a $28.00 price objective for the company in a research note on Saturday, July 9th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Loxo Oncology currently has a consensus rating of “Buy” and a consensus price target of $29.60.

The stock’s 50-day moving average price is $25.68 and its 200-day moving average price is $23.91. The firm’s market capitalization is $577.13 million.

Loxo Oncology (NASDAQ:LOXO) last released its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.63) by $0.14. Equities analysts predict that Loxo Oncology Inc. will post ($2.83) EPS for the current year.

In other Loxo Oncology news, Director David P. Bonita sold 447,857 shares of the company’s stock in a transaction on Wednesday, August 10th. The stock was sold at an average price of $26.96, for a total transaction of $12,074,224.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Keith T. Flaherty sold 15,000 shares of the company’s stock in a transaction on Thursday, August 11th. The stock was sold at an average price of $26.00, for a total value of $390,000.00. Following the sale, the director now owns 60,482 shares of the company’s stock, valued at $1,572,532. The disclosure for this sale can be found here.

Loxo Oncology, Inc is a United States-based biopharmaceutical company. The Company is engaged in developing selective medicines for patients with genetically defined cancers. Its pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.